Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of ML-007C-MA in adults with Alzheimer's disease psychosis
2025-521757-16-00Phase 2Authorised
- Sponsor
- MapLight Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, open-label, single-arm trial of ML-007/PAC in Alzheimer's disease (AD), sponsored by MapLight Therapeutics. Primary endpoint: Incidence of TEAEs, treatment-emergent SAEs, and TEAEs leading to study discontinuation. Planned start Jul 2026; status: authorised.
02
Drugs
ML-007/PAC
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2025-521757-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521757-16-00.